SEC EDGARJUN 162 min read$PCSA

SKIBSTED RUSSELL purchased $6K of PCSA

SKIBSTED RUSSELL (Chief Financial Officer) purchased 2,654 shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.22 on 2026-06-15.

Original reporting

SEC EDGAR · SKIBSTED RUSSELL

Published Jun 16, 2026, 8:23 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 16, 2026, 8:25 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PCSA

Bullish

low confidence

Mentioned

$PCSA

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PCSABullishLow

Why it matters

The newest fact is the CFO’s direct open-market purchase (2,654 shares) at a stated price, which may slightly improve sentiment but does not change fundamentals on its own.

Market read

Traders may treat this as a small sentiment input for PCSA, but it lacks fundamental catalysts (no guidance, trial, or corporate action).

What to watch

The article provides only one transaction size and price; traders may want to check prior insider activity frequency and whether other officers/10% holders also bought or sold.

Relevance 4/10Novelty 6/10Timing: filed 2026-06-16 (after 2026-06-15 purchase)

Background

This is an SEC Form 4 insider transaction disclosure for Processa Pharmaceuticals, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PCSABullishLow confidence

Context

Form 4 shows CFO SKIBSTED RUSSELL bought 2,654 shares of Processa Pharmaceuticals at $2.2200 on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with no accompanying guidance, trial, or deal information.

Market effects

Sector

No sector-level read-across; this is company-specific insider activity only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be driven by diversification, liquidity needs, or routine compensation-related behavior; without a 10b5-1 plan or larger pattern, signal strength is limited.

Key entities

issuer
Processa Pharmaceuticals, Inc.
Company whose shares were purchased by its CFO, disclosed via SEC Form 4.
insider
SKIBSTED RUSSELL
Chief Financial Officer who reported the direct open-market purchase.

Read at source ← All news

AUG 5

$PCSAMed

Processa Pharmaceuticals

Processa Pharmaceuticals (Nasdaq: PCSA) completed a July 2026 acquisition of Vidya Therapeutics, adding CNS-penetrant BTK inhibitor VT-7208 and shifting focus to immune-mediated diseases. Vidya holders received about 46% and private placement investors about 52.6%, leaving prior Processa holders about 0.9%. A $200M private placement funds operations into 2H 2029; Phase II starts planned in 2H 2026 (food allergy, CSU) and 1H 2027 (RMS).

thepharmaletter.com6 min

JUL 31

$VTRSMed

Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals

The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac

rttnews.com7 min

JUL 31

$PCSAHighAI 9/10

Processa Pharmaceuticals Acquires Vidya Therapeutics, Launch $200M Financing; Stock Down

Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biotechnology company, has acquired privately held Vidya Therapeutics, Inc. and simultaneously raise approximately $200 million through a private financing. Vidya's lead candidate, VT-7208, is a next-generation CNS-penetrant Bruton's tyrosine kinase inhibitor (BTKi) being developed for immune-mediated diseases like food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).

rttnews.com5 min

JUL 30

$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min

JUL 29

$PCSAMedAI 9/10

Processa Pharmaceuticals To Acquire Vidya Therapeutics, Launch $200M Financing; Stock Down

Processa Pharmaceuticals (PCSA) will acquire privately held Vidya Therapeutics and raise about $200M via a private financing. Vidya’s lead candidate VT-7208 is a CNS-penetrant BTK inhibitor for food allergy, CSU, and RMS. Deal terms include 558,398 PCSA shares plus preferred shares; financing priced at $1,221.19/share. Expected close July 30, 2026; PCSA stock fell 38% to $1.88.

rttnews.com4 min